About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« The Bell Finally Tolls for Peter Rost | Main | Home Sweet Home »

December 4, 2005

Not On the Same Page

Email This Entry

Posted by Derek

I mentioned phosphatase inhibitors while talking about okadaic acid the other day, and that brings me to a paper from the journal ChemBioChem (6, 1749) that I was recently reading. It's a collaboration from six German academic groups, led by one at the Max Planck Institute for Molecular Physiology in Dortmund. And there are some things about it that just don't seem to make much sense.

On the surface, everything's fine. They're investigating some cyclic peptide derviatives called stevastelins, which are microbial natural products known to show some phosphatase inhibitor activity. They produced some synthetic analogs of the natural products and ran them against several phosphatases of interest. They then turned around and did the same thing with some analogs of two more phosphatase-inhibiting natural products, roseophilin and prodigiosin. (For those of you who've done some bacteriology, that first compound is responsible for the red color of Serratia marcesens colonies).

Then the paper makes a sharp turn, as they move on to a 20,000 compound library that's been assembled by a German academic team. They screened this against their panel of phosphatase enzymes, and came up with 8 or 10 pyrrolobenzoic acid structures that showed some inhibitory activity. End of paper.

Well, the way I've presented this, it sounds like a fairly reasonable paper, if a bit of a hodgepodge. But it's the way everything's presented that makes me wonder. For example, their first group of stevastelin analogs is (for the most part) inactive against the five phosphatases they assayed. One of them hits the Cdc25a enzyme, one of them hits PTP1B, and one of them is active against MptpA, all of which are legitimate drug targets. But these compounds are all around 10 to 15 micromolar, which potency doesn't exactly make me leap up out of my chair.

But the authors refer to this as "pronounced selectivity for individual phosphatases". If you read the fine print, the "not active" values are compounds that were 30 micromolar and worse, so we could easily be looking at just two- or three-fold selectivity here. That is not my definition of "pronounced". Add that to the very weak potency, and you have results that I would toss if I saw them come out of a screening run. As a medicinal chemist, I'd start to get really interested at about a hundred times the potency of these compounds, and I'd be willing to bet that by that time the selectivity, if it's really there, would be long gone.

Their other natural product analogs are similar - one's as good as 3 micromolar against PTP1B, but others start to hit the 30 micromolar ceiling of the assay again. Even the active compound has a very unappealing chemical structure, which would only be developed by a desperate drug company indeed. (I particularly enjoy one of them that's reported against MptpA as "28.7 +/- 9.7" micromolar).

What's also irritating is the statement the authors make to justify all this: "We have previously forwarded the notion that biologically active natural products should be regarded as evolutionarily selected and biologically prevalidated starting points for inhibitor development." I'm glad they brought that up, since drug development from natural products has only been a popular technique for a century or so. The problem, as they're demonstrating here, is that if these compounds really are evolutionarily selected as phosphatase inhibitors, and the last hundred million years have only given you micromolar potency, then the odds of being able to push that lower by making half a dozen analogs are rather slim.

And that brings us to their screening efforts. Their compound library is "selected due to their diverse representation of reportedly bioactive scaffold elements". But 20,000 small molecules, however carefully selected, is not a very large collection. And when you get down to it, our compound collections in the drug industry are also supposed to represent a lot of reportedly bioactive scaffolds, and most of them are a couple of orders of magnitude larger.

The compounds from the screen are all micromolar. One of them looks a bit interesting, and possibly selective between the two kinases they ran it against. (What happened to the other enzymes by this point in the paper, I wonder?) I wouldn't want to try to develop these guys, but with the application of a lot of time, money, and effort, you might be able to get somewhere. Or you might wipe out within six months, which is how a lot of projects go, even the ones with better starting points than this, which is most of them.

Ah, but the authors are more optimistic than I am, because (I suspect) they haven't actually tried to do any drug development. "Further application of medicinal chemistry methodologies should allow for the development of more potent inhibitors for subsequent biological investigations in iterative cycles", they say. Oh, yes. Shouldn't it always?

Why am I going on at this length? Because I think that this paper illustrates a general problem: many academic labs do not understand what drug discovery entails, and (worse) they don't realize that they don't understand. The attitude shown here - presenting a few micromolar compounds as fine lead compounds and saying that med-chem should be able to sort things out - would actually be a good way to get fired at most companies. If this paper's data were somehow presented to me as a rationale for starting a project, I would create a distraction and dive for the door. No, there's still a long way to go.

Comments (7) + TrackBacks (0) | Category: Academia (vs. Industry)


1. Dr Snowboard on December 5, 2005 3:32 AM writes...

I agree completely - it's often what isn't said which is more revealing in these kinds of papers. At risk of provoking the modelling fraternity, the papers like
(this one) where a hyped approach results in an example compound that would also be thrown back in the pond by most medicinal chemists also gets me irritated. Or maybe I'm just a luddite.

Permalink to Comment

2. Jerry on December 5, 2005 9:49 AM writes...

Just FYI, the extremely long URL in Dr. Snowboard's comment makes this article bleed way off the right side of my page. It's quite difficult to read this way.

Permalink to Comment

3. Derek Lowe on December 5, 2005 11:32 AM writes...

I just went in and tagged the link to clear things up. (And yes, that's the only sort of thing that'll make me go in and edit someone's comment).

Permalink to Comment

4. GATC on December 5, 2005 11:55 AM writes...

This sort of thing should not be a big shock folks. The literature has been cluttered with cast-off data for decades now and it is not just the academic labs doing it. Nor is it just the med. chem/pharma literature.

I've seen it from the big pharmas too. Groups not being able to publish on the good stuff, at least not until it is in early clinical, often make due by publishing on the suboptimal stuff, or perhaps things they might like to out-license to the unsuspecting willing to take more of a risk.

As far as the published cast-offs, the blame is squarely with the journal and the editors/reviewers. If these guys really know the field and the extant literature, then they can set the standard of publication to any level they want.

Permalink to Comment

5. Molecula on December 6, 2005 3:33 AM writes...

Isn't the purpose of the 20,000 compounds library a fragment-based approach? Would that not explain why it isn't a very large collection and also why the hits are just micromolar?
"One of them looks a bit interesting, and possibly selective between the two kinases they ran it against." Did you mean phosphatases instead of kinases?

Permalink to Comment

6. Derek Lowe on December 6, 2005 9:07 AM writes...

The only reason I read the paper was the mention of a fragment-based approach in the title, which is an area I'm interested in. But that only comes up in the very last part, with the compound library. And it's not too useful - these are indeed fragments, but there's no apparent thought given to how they're to be linked to other fragments or elaborated. Just "standard medicinal chemisty should fix it all up."

The natural product derivatives they show aren't supposed to be fragments, and they're all micromolar, too. . .

Permalink to Comment

7. milo on December 6, 2005 12:01 PM writes...


As a resident in the great white tower, I can tell you that there is a pervasive notion that academics not only know med chem, but are better at it than industry. Well, let me back up, not ALL academics think this way...but a lot do (
this post
). :-)

I like reading papers that say that something is a "promising new treatment for blah blah blah". Those types of phases should be relegated solely to grant proposals and in talking about things in Phase II-III trials. For some reason, a lot of academic groups feel the need to justify their research by making these bold statements.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

XKCD on Protein Folding
The 2014 Chemistry Nobel: Beating the Diffraction Limit
German Pharma, Or What's Left of It
Sunesis Fails with Vosaroxin
A New Way to Estimate a Compound's Chances?
Meinwald Honored
Molecular Biology Turns Into Chemistry
Speaking at Northeastern